Hyderabad, Aug 5: Covaxin, India’s indigenous Covid-19 vaccine developed by Hyderabad-based Bharat Biotech, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Hungarian authorities.
The approval received is from the National Institute of Pharmacy and Nutrition Hungary certifying the GMP for the manufacture of Covaxin.
The certificate of GMP is now listed on the EudroGMDP database, which is the database of the European Community of manufacturing authorizations and certificate of the GMP.
Bharat Biotech intends to submit documentation for Emergency Use Authorisation (EUA) in several additional countries worldwide.
Taking to micro-blogging site twitter on Thursday, Bharat Biotech said: “Another milestone in our account as Covaxin receives GMP certificate from Hungary. This marks the 1st EudraGDMP compliance certificate received by BB from European regulators.”
With this approval, Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines of global quality standards and moving forward in the ongoing fight against the Covid-19 pandemic.
The recognition complements our commitment of driving world class innovation and being a frontrunner in the research and development of vaccines.